Renaissance Technologies
ARQT icon

Renaissance Technologies’s Arcutis Biotherapeutics ARQT Stock Holding History

Renaissance Technologies’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.4M Buy
440,999
+167,000
+61% +$4.26M 0.02% 948
2025
Q4 		$7.96M Buy
+273,999
New +$7.01M 0.01% 1038
2025
Q2 		– Sell
-21,799
Closed -$341K – 3544
2025
Q1 		$341K Buy
21,799
+10,700
+96% +$151K ﹤0.01% 2881
2024
Q4 		$155K Sell
11,099
-181,000
-94% -$1.98M ﹤0.01% 3222
2024
Q3 		$1.79M Buy
+192,099
New +$1.9M ﹤0.01% 2098
2024
Q1 		– Sell
-395,100
Closed -$1.28M – 3689
2023
Q4 		$1.28M Buy
+395,100
New +$1.07M ﹤0.01% 2242
2022
Q4 		– Sell
-65,000
Closed -$1.24M – 4099
2022
Q3 		$1.24M Buy
65,000
+54,200
+502% +$1.23M ﹤0.01% 2366
2022
Q2 		$230K Buy
+10,800
New +$222K ﹤0.01% 3584
2020
Q3 		– Sell
-27,700
Closed -$838K – 3359
2020
Q2 		$838K Buy
+27,700
New +$801K ﹤0.01% 2634

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return